Lamotrigine
As of the edition of 20 October 2026, Lamotrigine is a small molecule: marketed, first approved in 1994 (CH); acts on SCN10A, SCN11A and SCN1A and 7 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2008
- Kind
- Small molecule
- Brand name
- Lamictal
- First approved
- 23 December 1994 (CH)
- Approvals on record
- 35 in 7 regions
- Holder of the most recent approval
- Owp Pharmaceuticals; 3 holders in all
- Registered trials
- 141, 12 stopped early
- Disease areas
- Nervous system; Mental health; Chemically induced; Immune system; Inherited and neonatal; Nutrition and metabolism
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
9 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product9 company-target rows are on route B because of Lamotrigine.
See the 9 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| SCN1A | Sodium channel protein type 1 subunit alpha | P35498 |
| SCN4A | Sodium channel protein type 4 subunit alpha | P35499 |
| SCN7A | Sodium channel protein type 7 subunit alpha | Q01118 |
| SCN5A | Sodium channel protein type 5 subunit alpha | Q14524 |
| SCN9A | Sodium channel protein type 9 subunit alpha | Q15858 |
| SCN2A | Sodium channel protein type 2 subunit alpha | Q99250 |
| SCN3A | Sodium channel protein type 3 subunit alpha | Q9NY46 |
| SCN11A | Sodium channel protein type 11 subunit alpha | Q9UI33 |
| SCN8A | Sodium channel protein type 8 subunit alpha | Q9UQD0 |
| SCN10A | Sodium channel protein type 10 subunit alpha | Q9Y5Y9 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 29 | 20 | 3 | 2 |
| Phase 1 | 39 | 37 | 0 | 2 |
| Phase 2 | 16 | 11 | 0 | 3 |
| Phase 3 | 30 | 24 | 1 | 5 |
| Phase 4 | 27 | 25 | 0 | 0 |
| All trials | 141 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| GSK | Applicant and Lead sponsor of trials | 1994 to now |
| Owp Pharmaceuticals | Later holder | 2025 to now |